Latest Investment News

Kingfisher Mining has confirmed two new rare earth element lodes and reported exceptional copper assays, bolstering its position in the Gascoyne region amid ongoing strategic diversification.

Bellevue Gold Limited reports a robust December 2024 quarter with rising grades and tonnages, setting the stage for a significant production ramp-up and cost reductions in H2 FY25. The company also advances its commitment to sustainability, aiming for net-zero greenhouse gas emissions by 2026.

De Grey Mining reports outstanding infill drilling results at the Eagle deposit within the Hemi Gold Project, highlighting significant mineralisation extensions and reinforcing the case for future underground mining development.

Gold Road Resources projects a significant production increase at Gruyere in 2025 and has initiated underground drilling to potentially extend mine life beyond 2032.

Aurora Labs has secured significant contracts in the Defence sector, advancing its micro gas turbine technology and expanding production capabilities following a successful capital raise.

Butn Limited reported a modest net cash increase from operating activities in the December 2024 quarter, ending with a strong cash balance of $16.8 million. The fintech company’s latest cash flow report reveals ongoing investment and notable payments to related parties.

AIC Mines delivered a robust December quarter with record copper production at Eloise and promising exploration results at Jericho, underpinning its growth strategy.

Platina Resources reports promising gold mineralisation at its Challa Gold Project and secures a government grant to fund deep drilling at Xanadu, maintaining a strong cash position of $12.3 million.

Telix Pharmaceuticals has finalized its acquisition of RLS (USA) Inc., significantly expanding its radiopharmaceutical footprint across the United States with a network of over 30 radiopharmacies.

Veris Limited has reported a remarkable 212% increase in profit before tax for H1 FY25, driven by a strategic pivot towards higher-margin projects and successful restructuring efforts. Despite a slight revenue dip, the company’s strong order book and cash position signal robust growth potential.

Zelira Therapeutics has received a fourth funding tranche, bringing total investment to US$3.25 million to support FDA clinical trials of its HOPE® 1 cannabinoid medicine targeting irritability in autism spectrum disorder and Phelan-McDermid Syndrome.

Mayfield Group Holdings Limited has announced a fully franked ordinary dividend of AUD 0.01 per share, signaling steady returns for shareholders with payment scheduled for mid-February.